The company said the less expensive drugs could decrease costs by 20-30 percent when using European market as a model. However, Steven Lucio, director of pharmacy clinical solutions for Novation, said implementation of biosimilars will be a complicated process. Novation plans to expand two of its resources, the Drug Monograph Service and the biannual Drug Price Forecast, to include the availability of biosimilars.
Related Articles on the Supply Chain:
Developing and Launching a Long-Sleeved Scrub: Q&A With Myrna Chang of CA’s O’Connor Hospital and Jennifer Walrich of Medline
Counterfeit Version of Cancer Drug Avastin Found in U.S.
GHX to Create Industry’s First Implantable Devices Supply Chain Solution for Physician Preference Items
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.